In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Matinas BioPharma (MTNB – Research Report), with a price target of $3.00. The company's shares closed last Monday at $0.79. According to TipRanks.com, Fein has 0 stars on 0-5 stars ranking scale with an average return of -5.3% and a 37.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Amylyx Pharmaceuticals Inc, and Deciphera Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Matinas BioPharma with a $3.00 average price target.
https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-matinas-biopharma-mtnb?utm_source=advfn.com&utm_medium=referral
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Matinas Biopharma Charts.
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Matinas Biopharma Charts.